



Claims

1. A compound of formula (I)



that is 6-(2-((4-amino-3-(3-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl) methyl)-3-(2-chlorobenzyl)-4-oxo-3,4-dihydroquinazolin-5-yl)-*N,N*-bis(2-methoxyethyl)hex-5-ynamide in solid crystalline anhydrous form.

2. A compound of formula (I)



that is 6-(2-((4-amino-3-(3-hydroxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl) methyl)-3-(2-chlorobenzyl)-4-oxo-3,4-dihydroquinazolin-5-yl)-*N,N*-bis(2-methoxyethyl)hex-5-ynamide in the form of a solid crystalline hydrate.


3. A compound according to claim 1, wherein the compound of formula (I) is in solid crystalline form having the X-ray powder diffraction pattern substantially as shown in Figure 2.

4. A compound according to claim 1, wherein the compound of formula (I) is in solid crystalline form having a X-ray powder diffraction pattern containing one, two, three or four peaks selected from (± 0.2) 17.6, 18.4, 22.5 and 24.2 degrees 2-theta.
5. A compound according to claim 2, wherein the compound of formula (I) is in solid crystalline form having the X-ray powder diffraction pattern substantially as shown in Figure 1.
6. A compound according to claim 2 wherein the compound of formula (I) is in solid crystalline form having a X-ray powder diffraction pattern containing one, two, three, four, five, six or seven peaks selected from (± 0.2) 9.6, 13.3, 13.9, 17.0, 18.9, 20.3 and 23.1 degrees 2-theta.
7. A compound according to any one of claims 1 to 6 for use as a medicament.
8. A pharmaceutical composition comprising a compound according to any one of claims 1 to 7 in admixture with one or more pharmaceutically acceptable diluents or carriers.
9. A pharmaceutical composition according to claim 8 which contains lactose (e.g. α -lactose monohydrate) as a diluent or carrier.
10. A pharmaceutical composition according to claim 8 or 9 which contains a stabilizing agent selected from metal salts of stearic acid and metal salts of stearyl fumarate.
11. A pharmaceutical composition according to claim 10 wherein the stabilizing agent is a metal salt of stearic acid such as magnesium stearate.
12. A pharmaceutical composition according to any one of claims 8 to 11 which comprises the compound of formula (I) in micronized form.
13. A compound according to any one of claims 1 to 7 or a pharmaceutical formulation according to any one of claims 8 to 12 for use in the treatment or prevention of a condition selected from:
COPD (including chronic bronchitis and emphysema), asthma including paediatric asthma, cystic fibrosis, sarcoidosis, idiopathic pulmonary fibrosis, cachexia and inhibition of the growth and metastasis of lung tumours including non-small cell lung carcinoma.

14. Use of a compound according to any one of claims 1 to 7 or a pharmaceutical formulation according to any one of claims 8 to 12 in the manufacture of a medicament for the treatment or prevention of a condition selected from:
COPD (including chronic bronchitis and emphysema), asthma including paediatric asthma, cystic fibrosis, sarcoidosis, idiopathic pulmonary fibrosis, cachexia and inhibition of the growth and metastasis of lung tumours including non-small cell lung carcinoma.
15. A method of treatment of a condition selected from:
COPD (including chronic bronchitis and emphysema), asthma including paediatric asthma, cystic fibrosis, sarcoidosis, idiopathic pulmonary fibrosis, cachexia and inhibition of the growth and metastasis of lung tumours including non-small cell lung carcinoma which comprises administering to a subject an effective amount of a compound according to any one of claims 1 to 7 or a pharmaceutical formulation according to any one of claims 8 to 12.
16. A process for the preparation of a compound of formula (I) in solid crystalline anhydrous form according to any one of claims 1, 3 or 4 comprising the step of crystallizing a compound of formula (I) from dry 1-propanol.
17. A process according to claim 16, wherein the crystallization step involves cooling from elevated temperature.
18. A process for the preparation of a compound of formula (I) in the form of a solid crystalline hydrate according to any one of claims 2, 5 or 6 comprising the step of crystallizing a compound of formula (I) from dichloromethane optionally in mixture with methanol.
19. An inhalation device comprising one or more doses of a pharmaceutical formulation according to any one of claims 8 to 12.

Claims

1. A compound of formula (I)



that is 6-(2-((4-amino-3-(3-hydroxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl) methyl)-3-(2-chlorobenzyl)-4-oxo-3,4-dihydroquinazolin-5-yl)-N,N-bis(2-methoxyethyl)hex-5-ynamide in solid crystalline anhydrous form.

2. A compound according to claim 1, wherein the compound of formula (I) is in solid crystalline form having the X-ray powder diffraction pattern substantially as shown in Figure 2.
3. A compound according to claim 1, wherein the compound of formula (I) is in solid crystalline form having a X-ray powder diffraction pattern containing peaks at (± 0.2) 17.6, 18.4, 22.5 and 24.2 degrees 2-theta.
4. A compound according to any one of claims 1 to 3 for use as a medicament.
5. A pharmaceutical composition comprising a compound according to any one of claims 1 to 3 in admixture with one or more pharmaceutically acceptable diluents or carriers.
6. A pharmaceutical composition according to claim 5 which contains lactose as a diluent or carrier.
7. A pharmaceutical composition according to claim 6 wherein the lactose is alpha-lactose monohydrate.
8. A pharmaceutical composition according to any one of claims 5, 6 and 7 which contains a stabilizing agent selected from metal salts of stearic acid and metal salts of stearyl fumarate.
9. A pharmaceutical composition according to claim 8 wherein the stabilizing agent is a metal salt of stearic acid.
10. A pharmaceutical composition according to claim 9 wherein the stabilizing agent is magnesium stearate.
11. A pharmaceutical composition according to any one of claims 5 to 10 which comprises the compound of formula (I) in micronized form.
12. A compound according to any one of claims 1 to 3 or a pharmaceutical composition according to any one of claims 5 to 11 for use in the treatment or prevention of a condition selected from:

COPD (including chronic bronchitis and emphysema), asthma including paediatric asthma, cystic fibrosis, sarcoidosis, idiopathic pulmonary fibrosis, cachexia and inhibition of the growth and metastasis of lung tumours including non-small cell lung carcinoma.
13. A process for the preparation of a compound of formula (I) in solid crystalline anhydrous form according to any one of claims 1 to 3 comprising the step of crystallizing a compound of formula (I) from dry 1-propanol.
14. A process according to claim 13, wherein the crystallization step involves cooling from elevated temperature.
15. An inhalation device comprising one or more doses of a pharmaceutical composition according to any one of claims 5 to 11.